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. Milic´evAbstract Background: The unfavourable side-effects of late-stage pancreatic cancer treat-
ments call for non-toxic and effective therapeutic approaches. We compared the overall sur-
vival (OS) of patients receiving an extract of Viscum album [L.] (VaL) or no antineoplastic
therapy.
Methods: This is a prospective, parallel, open label, monocentre, group-sequential, random-
ised phase III study. Patients with locally advanced or metastatic cancer of the pancreas were
stratiﬁed according to a binary prognosis index, composed of tumour stage, age and perfor-
mance status; and were evenly randomised to subcutaneous injections of VaL extracts or no
antineoplastic therapy (control). VaL was applied in a dose-escalating manner from 0.01 mg
up to 10 mg three times per week. Patients in both groups received best supportive care. The
primary end-point was 12-month OS, assessed in a group-sequential analysis.
Findings: We present the ﬁrst interim analysis, including data from 220 patients. Baseline
characteristics were well balanced between the study arms. Median OS was 4.8 for VaL andhed by Elsevier Ltd.
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W. Tro¨ger et al. / European Journal of Cancer 49 (2013) 3788–3797 37892.7 months for control patients (prognosis-adjusted hazard ratio, HR = 0.49; p < 0.0001).
Within the ‘good’ prognosis subgroup, median OS was 6.6 versus 3.2 months (HR = 0.43;
p < 0.0001), within the ‘poor’ prognosis subgroup, it was 3.4 versus 2.0 months respectively
(HR = 0.55; p = 0.0031). No VaL-related adverse events were observed.
Conclusion: VaL therapy showed a signiﬁcant and clinically relevant prolongation of OS. The
study ﬁndings suggest VaL to be a non-toxic and effective second-line therapy that offers a
prolongation of OS as well as less disease-related symptoms for patients with locally advanced
or metastatic pancreatic cancer.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Patients suﬀering from pancreatic cancer in a locally
advanced or metastatic stage do not have many treat-
ment options if their general condition is bad or if stan-
dard therapies have failed.1–4 Recent studies on second-
line therapies for pancreatic cancer showed beneﬁt5,6;
however, Gemcitabine, 5-FU, capecitabine and combi-
nations of Gemcitabine with capecitabine, erlotinib,
oxaliplatin and cisplatin have serious side-eﬀects leading
to poor compliance of patients and physicians. Best
Supportive Care (BSC) is often the only option,7 and
looking for other therapeutic approaches is desirable.
Medicinal plants have a long tradition in the treat-
ment of cancer and play a major role in the development
of new drugs today. Over 60% of currently used anti-
cancer agents originally derive from natural products.8
In central Europe, extracts of Viscum album [L.] (VaL)
are registered for parenteral use and are widely used in
adjuvant and palliative cancer therapy, alone or in addi-
tion to conventional therapies.9
VaL contains a variety of biologically active
constituents such as lectins, viscotoxins and other
low-molecular-weight proteins; furthermore, a chitin-
binding agglutinin, oligo- and polysaccharides,
ﬂavonoids, vesicles, triterpene acids and others.10 The
manufacturing of VaL adheres to ‘good Medical
Practise’ – requirements for injectable medications; the
typical proteins of VaL (mistletoe lectins and viscotoxins)
are analysed to ensure consistent quantity and quality.
Whole VaL extracts as well as several of the compounds
are cytotoxic, and the lectins in particular have strong
apoptosis-inducing eﬀects via expression of mitochon-
drial Apo2.7 molecules.11 VaL and its compounds
stimulate the activation of monocytes/macrophages,
granulocytes, natural killer cells, T-cells and dendritic
cells; they induce granulocyte–macrophage colony-
stimulating factor, tumour necrosis factor a, interferon
c and a variety of cytokines, and they enhance
endorphins in vivo.9,10,12 Accordingly, low-dose but not
high-dose VaL-lectin-I reduces melanoma growth in a
mouse model, probably by immunosignalling.13
Intratumoral injections of VaL result in partial and
complete remissions in an animal model using human
pancreatic cancer xenografts14 and also in patients with
inoperable pancreatic carcinoma.15A phase I interaction study of VaL and gemcitabine
in patients with advanced solid tumours demonstrated
VaL to be safe and well tolerated, allowing a 30% higher
gemcitabine dose to be applied. Gemcitabine pharmaco-
kinetics was not aﬀected.16 A recent review of safety
data concerning higher VaL dosages conﬁrmed the
favourable safety proﬁle17 which is particularly desirable
for late-stage cancer patients.
Here we present a phase III, open-label, randomised,
group-sequential study (ISRCTN70760582). It investi-
gated whether VaL treatment has an eﬀect on overall
survival (OS) in patients with locally advanced or meta-
static cancer of the pancreas. Because in countries with
widespread use of VaL there is a low patient compliance
constraining the conduct of randomised VaL trials,18 we
conducted this study in Serbia where VaL therapy is
practically unknown. We report the results of the ﬁrst
interim analysis.
2. Methods
This is a prospective randomised open-label study on
overall survival. Blinding is not essential in cancer stud-
ies with overall survival as primary end-point according
to the Food and Drug Administration (FDA) guide-
lines.19 The study was conducted at the Hepato-Biliary
Surgical Unit of the First Surgical Clinic of the Clinical
Centre of Serbia (CCS), Belgrade, Serbia. Patients were
referred to the study site from seven diﬀerent centres in
Serbia. The study was conducted according to the Dec-
laration of Helsinki and was approved by the ethics
committee of the Clinical Centre of Serbia in Belgrade
(No. 60/6 from 04.03.2008) and by the Serbian Drug
Agency (No. 587/2008/4000 from 10.11.2008). All
patients provided written informed consent before study
entry. The study was subject of GCP-conform on-site
monitoring. Two independent audits reported no critical
or major ﬁndings relating to the conduct of the study.
Results of the interim analysis were reviewed by an
Independent Data Monitoring Committee (IDMC).
2.1. Patients
Inclusion criteria for patients were: adults agedP18;
with locally advanced or metastatic cancer of the pan-
creas (Union for International Cancer Control [UICC]
3790 W. Tro¨ger et al. / European Journal of Cancer 49 (2013) 3788–3797stage III/IV); with any history of previous therapies but
not eligible for antineoplastic therapies anymore; leuco-
cytesP 3000 /mm3; plateletsP 100,000 /mm3; serum
creatinine 6 2 mg%; serum glutamic oxaloacetic trans-
aminase (SGOT) 6 2.5-fold upper institutional limit;
serum glutamic pyruvic transaminase (SGPT) 6 2.5-fold
upper institutional limit; negative pregnancy test and
contraception (where appropriate); and no other anti-
neoplastic therapies planned during the study except
5-ﬂuorouracil (FU)/leucovorin for symptom alleviation.
After the ﬁrst 47 patients, the inclusion criteria SGOT,
SGPT and creatinine were omitted by protocol amend-
ment, since many of the screened patients had very
advanced disease and failed to meet these criteria.
Speciﬁc exclusion criteria were: life expectancy less
than 4 weeks; weight lossP 20% in the preceding
6 weeks; brain metastasis.
2.2. Patient assignment
The Clinical Centre of Serbia (CCS), Belgrade, has
about 3700 hospital beds and about 880,000 ambulatory
patients. Study centre is the First Surgical Clinic of
CCS, the main referral centre for surgical treatment of
patients with hepatobiliary and pancreatic malignancies
in Serbia. Decisions on treatments of cancer patients are
made in a weekly multidisciplinary oncology consulta-
tion based on local regulations: inoperable patients with
advanced or metastatic pancreatic cancer, not willing to
receive chemotherapy or with at least one of the follow-
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Fig. 1. Flow chart according to Consolidated Standards of ReportCooperative Oncology Group (ECOG) > 2, Biliru-
bine > 50 lmol/l, transaminases > 100 U/l, leuko-
cytes > 10.0*109 /l, missing histological conﬁrmation of
the disease and therefore not eligible for chemotherapy.
After eligibility assessment, signed and witnessed
informed consent, and after passing all in- and exclusion
criteria, patients were enrolled into the study (Fig. 1).
Patients were stratiﬁed into two groups regarding
their expected prognosis: ‘Poor prognosis’ was
deﬁned as presenting with at least two out of the three
following criteria: UICC class = IV; age > 65; and
ECOGP 2. All other patients were classiﬁed as
having ‘good prognosis’. Within each stratum,
patients were randomised 1:1 to either the VaL or
control group.
2.3. Study medication
The Viscum album (L.) extract (VaL) applied in this
study is an approved drug and has a marketing author-
isation under the name ‘Iscador Qu spezial’ in Ger-
many, Switzerland and Austria. It is extracted from
the mistletoe of oak trees (Qu = Quercus).The fresh
plant is fermented with special starter cultures (lactoba-
cilli). The drug substance Iscador is then diluted with
isotonic saline solution, sterile-ﬁltered and subsequently
ﬁlled into ampoules as an aseptic injection preparation.
The manufacturing adheres to GMP requirements for
injectable medications; typical proteins of VaL (mistle-
toe lectins and viscotoxins) are analysed to ensure con-
sistent quantity and quality.gibility (n=238)
Excluded (n=18)
- Not meeting inclusion criterion
(n=18)
- Refused to participate (n=0)
- Other reasons (n=0)
d (n=220)
Allocated to control (n=110)
- Received VaL (n=0)
- Did not receive VaL (n=110)
Discontinued study (n=5)
Reasons:
- Lost to follow-up (n=1)
- Medical contraindication (n=3)
- Withdrawal of consent (n=0)
- Non-compliance (n=1)
Analysed for efficacy (n=110)
Analysed for safety (n=110)
ing Trials (CONSORT). Abbreviation: VaL, Viscum album [L.].
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During the course of the study, all patients received
best supportive care which was individually tailored to
patient needs at the scheduled follow-up visits (at month
1, 2, 3, 6, 9 and 12), at additional intermediate consulta-
tion visits of patients in the study centre and by addi-
tional telephone consultations.
Patients in the VaL group received 1 ml subcutaneous
injections of VaL three times per week. Patients were
taught how to self-administer the subcutaneous injec-
tions of VaL. For the time intervals between the fol-
low-up visits at the study centre, patients were
provided with suﬃcient ampoules of VaL and syringes
for administration at home or at local health centres.
Injections were either self-administered or given by rela-
tives or nurses. VaL dosage was escalating: two injec-
tions of 0.01 mg, two of 0.1 mg, ﬁve of 1 mg, ﬁve of
2 mg and eight of 5 mg, followed by constant doses of
10 mg thrice weekly, maintained throughout the study.
In case of local inﬂammatory skin reactions >5 cm or
body temperature >38 C, Val was to be reduced to
the last well tolerated dosage.2.5. End-points
Our primary hypothesis was: Advanced pancreatic
cancer patients receiving VaL will show an improvement
of 12-month OS. Reference point for OS was the date of
inclusion into the study. Primary end-point was the date
of death from any reason, obtained from family mem-
bers and cross-checked by the Serbian residents’ regis-
tration oﬃce. This ﬁrst interim analysis included 220
patients enrolled in the study, using the intention-to-
treat approach.
The secondary end-points of this study were: quality
of life parameters, vital signs, performance status,
weight and concomitant medication. The respective
results will be published elsewhere.2.6. Safety
All 220 enrolled patients were included in the safety
evaluation.
At each visit, patients were asked for adverse events
which were documented according to the Common Tox-
icity Criteria for Adverse Events (CTCAE).
After the inclusion of the ﬁrst 47 patients, a more
consistent record of all adverse events was considered
desirable, and a standardised documentation of dis-
ease-related symptoms was additionally provided in
the case report form. These disease-related symptoms
consisted of weight loss, pain, loss of energy, nausea/
emesis, diarrhoea, anxiety, vertigo, jaundice and abnor-
mal values of bilirubin, SGOT and SGPT. Their severity
was rated according to CTCAE as: none, mild, moder-ate, severe and life-threatening or disabling. All patients
received diaries to document episodes of fever. VaL
patients were additionally asked to document the
applied dose and the occurrence of local skin reactions
at the injection site which are considered a desirable
immune response and not classiﬁed as an adverse event
in this study if less than 5 cm in diameter.2.7. Determination of the sample size
Previous VaL studies in patients with advanced pan-
creatic cancer showed a prolongation in median OS from
5 to 7 months, from which a hazard ratio of 0.714 could
be deduced.20,21 For a two-sided group-sequential
hypothesis test with two pre-planned interim analyses
including 50% and 75% of the foreseen total sample size,
respectively, assuming a power of 85% and 5% level of
signiﬁcance as well as an accrual period of 53 months
with an additional follow-up time of 12 months and an
even allocation scheme, it was estimated that 173 evalu-
able patients per group would be needed to conﬁrm a sta-
tistically signiﬁcant treatment eﬀect according to
Freedman’s formula.22 To account for dropouts the
study was designed for a maximum of 428 patients.2.8. Randomisation
A special department of the data management cre-
ated for each of the two prognosis strata a separate,
evenly balanced randomisation list with variable permu-
tation block sizes of 4, 6 and 8 using SAS version 9.1
(SAS Institute, Cary, NC, USA). Following these
two randomisation lists, one for each prognosis stratum,
two series of opaque and sealed consecutively numbered
allocation letters were produced and stored at the study
centre. When a patient had been included and attributed
to one of the prognosis strata, the investigator opened
the next consecutive allocation letter of that stratum
and assigned the patient, as determined in this letter,
either to the Val or the control group. The monitor
checked the sealed as well as the opened random letters
at each monitoring visit.2.9. Statistical methods
The study design is based on a group-sequential test
procedure with pre-planned analyses after 220, 320
and 428 patients meeting one of the oﬀ-study criteria.
An alpha-spending approach as suggested by Lan and
DeMets23 with an O’Brien/Fleming-like alpha spending
function was used to deﬁne the test boundaries of the
group-sequential procedure. The primary analysis
regarding OS uses a Cox Proportional Hazard Model
with treatment and prognosis groups as predictor vari-
ables to calculate the Z score needed for the group-
sequential procedure. Stagewise ordering was used to
Table 1
Demographic and clinical baseline-characteristics of 220 patients with
locally advanced or metastatic pancreatic cancer, treated with VaL
extracts or no antineoplastic therapy (control).
Patient
characteristic
Group
Control
(n = 110)
VaL
(n = 110)
Test (2-sided)
Gender
Male 63 (57.3%) 65 (59.1%) p = 0.891 FET
Female 47 (42.7%) 45 (40.9%)
Age (years)
Median 65 61 p = 0.097
Wilcoxon
Range 27–90 24–87
Race
Caucasian 110 (100%) 110 (100%) –
ECOG
0–1 56 (50.9%) 56 (50.9%) p = 1.000 FET
2–4 54 (49.1%) 54 (49.1%)
UICC
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limits for the prognosis-group-adjusted hazard rates.24
The non-parametric Kaplan–Meier product-limit esti-
mator of the survival function was used to visualise dif-
ferences between treatment groups and to calculate
median survival times.
The Wilcoxon rank sum test and Fisher’s exact test
were used to check the balance of demographic and clin-
ical baseline characteristics. Prognosis-group-adjusted
odds ratios for the occurrence of at least one adverse
event during the course of the study were calculated
by logistic regression. The worst reported post-baseline
CTCAE grade of a patient for each item of the dis-
ease-related symptom section was analysed by a Coch-
ran–Mantel–Haenszel test stratiﬁed for its baseline
value. All tests were two-sided, and a p-value of 0.05
was considered statistically signiﬁcant. The statistical
analysis was performed with SAS version 9.2.III 64 (58.2%) 57 (51.8%) p = 0.416 FET
IV 46 (41.8%) 53 (48.2%)
Prognosis group
Poor 56 (50.9%) 55 (50.0%) p = 1.000 FET
Good 54 (49.1%) 55 (50.0%)
Tumor-related surgery
No 9 (8.2%) 6 (5.5%) p = 0.594 FET
Yes 101 (91.8%) 104 (94.5%)
Aﬀected part of pancreas
Head 56 (50.9%) 58 (52.7%) p = 0.564 FET
Body 12 (10.9%) 12 (10.9%)
Tail 3 (2.7%) 7 (6.4%)
Head and body 18 (16.4%) 18 (16.4%)
Body and tail 21 (19.1%) 14 (12.7%)
Head, body and
tail
- (-%) 1 (0.9%)
TNM (T)
3 1 (0.9%) 2 (1.8%) p = 0.622 FET
4 109 (99.1%) 107 (97.3%)
X - (-%) 1 (0.9%)
TNM (N)
0 1 (0.9%) - (-%) p = 1.000 FET
1 13 (0.9%) 14 (12.7%)
X 96 (87.3%) 96 (87.3%)
TNM (M)3. Results
3.1. Patients’ characteristics
This ﬁrst interim analysis referred to 238 screened
patients, of whom 220 had been enrolled into the study
between January 2009 and December 2010 (Fig. 1).
Eighteen patients were not enrolled because their condi-
tion was too bad (major weight loss, life expectancy
<4 weeks). All enrolled patients had locally advanced
or metastatic pancreatic cancer: 195 patients were diag-
nosed during surgery and 25 were diagnosed by imaging
methods only. Baseline patient characteristics were well
balanced between VaL and control groups (Table 1).
Seven patients dropped out: two in the VaL group and
ﬁve in the control group (Fig. 1). None of the dropouts
were related to treatment with VaL. The recruitment
into this study was stopped due to proven eﬃcacy after
obtaining the decision of the IDMC in May 2012.0 64 (58.2%) 57 (51.8%) p = 0.416 FET
1 46 (41.8%) 53 (48.2%)
Abbreviations:Wilcoxon, Wilcoxon rank sum test; FET, Fisher’s Exact
test; ECOG, Eastern Cooperative Oncology Group (performance
scale); UICC, Union for International Cancer Control (for grading);
TNM, TNM classiﬁcation according to UICC; VaL, Viscum album
[L.].3.2. Treatment administration
During the study, patients in the VaL group received
three 1 ml subcutaneous injections of VaL per week. In
total, 8136 subcutaneous injections were recorded for
110 patients (per patient median = 61.5; minimum = 3;
maximum = 156). For all patients in the VaL group, dose
escalation followed the planned scheme without any need
for dose reduction. No patients in the control group
received VaL. All patients in both groups were provided
with best supportive care and none of them received 5-
FU/Leucovorin or any other antineoplastic therapies.3.3. Overall survival
Median OS for patients was 4.8 months in the VaL
group and 2.7 months in the control group (Fig. 2). Aprognosis-group adjusted hazard ratio (HR) of 0.49
(95% conﬁdence interval (CI) = 0.36–0.65, p < 0.0001)
was estimated by the group-sequential procedure.
Subgroup analysis for patients with ‘good prognosis’
showed a median OS of 6.6 months in the VaL group
compared to 3.2 months in the control group
(Chi2 = 15.5, HR = 0.43; 95% CI = 0.28–0.65,
p < 0.0001) (Fig. 3). For patients with ‘poor prognosis’
the median OS was 3.4 months and 2.0 months, respec-
Fig. 2. Kaplan–Meier estimates of 12-month overall survival of 220
patients with advanced or metastatic pancreatic cancer assigned to a
therapy with extract of VaL or to no antineoplastic therapy (Control).
Abbreviations: Cox, Cox regression adjusted for prognosis state; VaL,
Viscum album [L.]. Note: All patients surviving for more than
12 months are censored and therefore not at risk any more.
Fig. 3. Kaplan–Meier estimates of 12-month overall survival of 109
patients with advanced or metastatic pancreatic cancer assigned to a
therapy with extract of VaL or to no antineoplastic therapy (Control)
and good prognosis. Abbreviations: Cox, Cox regression; VaL, Viscum
album [L.].
Fig. 4. Kaplan–Meier estimates of 12-month overall survival of 111
patients with advanced or metastatic pancreatic cancer assigned to a
therapy with extract of VaL or to no antineoplastic therapy (Control)
and poor prognosis. Abbreviations: Cox, Cox regression; VaL, Viscum
album [L.].
Fig. 5. Forest plot (multivariate cox regression including interactions)
of the treatment eﬀect on 12-month overall survival of 220 patients
with advanced or metastatic pancreatic cancer assigned to a therapy
with extract of VaL or to no antineoplastic therapy (Control).
Abbreviations: ECOG, Eastern Cooperative Oncology Group (perfor-
mance scale); VaL, Viscum album [L.]. The squares represent the
hazard ratio and their sizes are proportional to the sizes of the
subgroups. The horizontal lines show the conﬁdence intervals.
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p = 0.0031) (Fig. 4). Seventeen patients in the VaL
group and no patient in the control group ended the
study with a regular exit visit after 12 months. Two
patients in the control group dropped out without an
exit visit, but survived study day 360. Subgroup analysesshowed superiority for the VaL group in all analysed
subsets (Fig. 5).
3.4. Safety
In the VaL group, 16 adverse events and one serious
adverse event (cerebral infarction) occurred in 11
patients; in the control group, 53 adverse events
Table 2
Summary of adverse event analysis: number of AEs by MedDRA
preferred term and CTCAE grade with total frequencyP2 in patients
with locally advanced or metastatic pancreatic cancer assigned to a
therapy with extract of VaL or to no antineoplastic therapy (Control).
Adverse event Grade Control n = 53
(100%)
VaL n = 17
(100%)
Back pain CTC
2
8 (15%) 4 (24%)
CTC
3
12 (23%) 0
Dyspepsia CTC
2
11 (21%) 2 (12%)
Dehydration CTC
2
6 (11%) 1 (6%)
Headache CTC
1
1 (2%) 0
CTC
3
1 (2%) 0
Metastases to liver CTC
1
2 (4%) 0
Urinary tract infection CTC
1
0 2 (12%)
Abdominal pain/upper
abdominal pain
CTC
1
1 (2%) 1 (6%)
CTC
2
1 (2%) 1 (6%)
Note: None of the adverse events was related to the therapy with VaL.
Abbreviation: VaL, Viscum album [L.].
The Medical Dictionary for Regulatory Activities (MedDRA).
3794 W. Tro¨ger et al. / European Journal of Cancer 49 (2013) 3788–3797occurred in 34 patients. The odds ratio of 0.25 (95%
CI = 0.12–0.52) calculated by logistic regression
adjusted for the prognosis group was in favour of the
VaL group. The most frequent adverse event (AE) was
back pain (four in the VaL group and 20 in the control
group; Table 2). None of the adverse events was causally
related to VaL.
Local side-eﬀects of VaL injections such as erythema
or swellings were reported in the diaries of 67 VaL
patients but were always below the AE-deﬁning size of
5 cm in diameter. The validity of the diary data, how-
ever, seemed questionable, since substantial number of
diary entries could not undoubtedly be attributed to
patients but may have been done by relatives or nurses.
Prevalence of pre-speciﬁed post-baseline disease-
related symptoms in patients was: pain (96.9%); loss of
energy (70.9%); abnormal SGPT (55.4%); abnormal
SGOT (50.6%); weight loss (42.5%); abnormal bilirubin
(38.1%); jaundice (26.0%); nausea/emesis (18.9%); diar-
rhoea and anxiety (both 2.4%). No cases of vertigo were
reported. In the VaL group, the frequency and severity
of post-baseline disease-related symptoms was signiﬁ-
cantly lower for: pain, weight loss, loss of energy, nau-
sea/emesis (p < 0.0001 for all parameters), diarrhoea
(p = 0.0033) and anxiety (p = 0.046) (Table 3).4. Discussion
In this randomised phase III study on patients with
locally advanced or metastatic cancer of the pancreas,patients in the VaL group had a signiﬁcant longer OS.
No VaL-related side-eﬀects were observed, and fewer dis-
ease-related symptoms were reported for patients in the
VaL group.
Based on the ﬁndings of this interim analysis, the
IDMC recommended the termination of the study,
and to give all study patients unrestricted access to
VaL therapy. However, due to the lack of a marketing
authorisation in Serbia, legal restrictions prohibit the
provision of any patient with VaL outside of the clinical
trial. Therefore, the local ethics committee allowed to
stop the recruitment after 376 patients and to treat
patients with VaL within the study.
The non-blinding of study treatment always is a
concern in conﬁrmatory clinical trials. However,
according to a FDA-guideline blinding is not essential
in cancer studies with overall survival as primary end-
point. And apart from that a recent Cochrane review25
on controlled trials comparing placebo groups with
untreated groups found no signiﬁcant eﬀects on contin-
uous or binary outcomes. Regarding our study, it may
be of concern that diﬀerent qualities of BSC may inﬂu-
ence the patients’ OS. To prevent such bias, we centra-
lised the medical care (BSC) during the study,
guaranteeing a high and equal standard of BSC for
both patient groups and prompting the patients to
come to the follow-up visits at the study centre. The
very low drop-out rate in both groups may be a sign
of the eﬀectiveness of this measure. Up to the point
of time of this interim analysis no diﬀerences in BSC
in the two groups were found.
Previous VaL studies on OS of cancer patients had
either an epidemiologic design20,26; had a small number
of participants or were not properly randomised27,28; or,
as criticised,27,28 may have had unbalanced baseline
characteristics and a large number of dropouts and
verum patients not receiving VaL,29 or too low doses.30
Strengths of the present study are its prospective ran-
domised study design, a suﬃcient number of partici-
pants, OS as primary end-point, baseline
characteristics balanced between groups, a small num-
ber of dropouts, all patients in the verum group receiv-
ing VaL treatment and suﬃcient VaL dosage.
The absence of a histopathological conﬁrmation of the
diagnosis for tumour identiﬁcation is justiﬁed by the high
risk of pancreatic ﬁstula for the patients when direct
tumour biopsy is taken and represents the institutional
policy: a histopathological examination is considered
unnecessary in local non-resectable stage of the disease
(inﬁltration of both superior mesenteric artery and vein,
inﬁltration ofmesentery root and inﬁltration of retroperi-
toneal space and major blood vessels) and in patients not
consenting in chemotherapy. Imaging of the tumour in
the pancreatic body and/or tail, andmetastasis in the liver
and/or spread in the peritoneum is also considered to be a
suﬃcient diagnosis.
Table 3
Summary of maximum post-baseline CTCAE grade of disease related symptoms of patients* with locally advanced metastatic pancreatic cancer
assigned to a therapy with extract of VaL or to no antineoplastic therapy (Control).
Symptom Grade Group
Control n = 51 (100%) VaL n = 76 (100%) Mantel–Haenszel** Chi2/p (2-sided)
Weight loss CTC 0 18 (35.3%) 74 (97.4%) 52.23/p < 0.0001
CTC 1 25 (49.0%) 2 (2.6%)
CTC 2 8 (15.7%) 0
Pain CTC 0 0 4 (5.3%) 26.90/p < 0.0001
CTC 1 12 (23.5%) 46 (60.5%)
CTC 2 38 (74.5%) 26 (34.2%)
CTC 3 1 (2.0%) 0
Loss of energy CTC 0 0 37 (48.7%) 40.39/p < 0.0001
CTC 1 44 (86.3%) 39 (51.3%)
CTC 2 7 (13.7%) 0
Nausea/emesis CTC 0 29 (56.9%) 74 (97.4%) 32.06/p < 0.0001
CTC 1 22 (43.1%) 2 (2.6%)
Diarrhea CTC 0 48 (94.1%) 76 (100%) 4.54/p = 0.0331
CTC 1 3 (5.9%) 0
Anxiety CTC 0 48 (94.6%) 76 (100%) 4.00/p = 0.0455
CTC 1 3 (5.9%) 0
Vertigo CTC 0 51 (100%) 76 (100%) –/–
Jaundice CTC 0 36 (70.6%) 58 (76.3%) 0.34/p = 0.5578
CTC 1 12 (23.5%) 12 (15.8%)
CTC 2 3 (5.9%) 6 (7.9%)
Bilirubin CTC 0 43 (59.7%) 61 (63.5%) 1.03/p = 0.3097
CTC 1 9 (12.5%) 14 (14.6%)
CTC 2 9 (12.5%) 12 (12.5%)
CTC 3 7 (9.7%) 8 (8.3%)
CTC 4 4 (5.6%) 1 (1.0%)
SGOT CTC 0 32 (44.4%) 51 (53.1%) 1.86/p = 0.1730
CTC 1 24 (33.3%) 31 (32.3%)
CTC 2 12 (16.7%) 11 (11.5%)
CTC 3 4 (5.6%) 3 (3.1%)
SGPT CTC 0 31 (43.1%) 44 (45.8%) 0.92/p = 0.3382
CTC 1 29 (40.3%) 43 (44.8%)
CTC 2 9 (12.5%) 8 (8.3%)
CTC 3 3 (4.2%) 1 (1.0%)
Abbreviations: CTCAE, common terminology for adverse events; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvic
transaminase; VaL, Viscum album [L.].
* Patients with symptom documentation that survived at least until visit 2 (=100%).
** Cochran–Mantel–Haenszel test, stratiﬁed for baseline value.
W. Tro¨ger et al. / European Journal of Cancer 49 (2013) 3788–3797 3795To assess the external validity, we compared the out-
come of our control group with that of untreated
patients as reported in the literature. The literature
search outcome of a previous review31 was updated in
January 2013 yielding 20 publications with OS times in
a total of 754 untreated patients with advanced or met-
astatic pancreatic cancer.31–50 The range of median sur-
vival times from 2.1 to 7.0 months (median = 3.9;
weighted mean = 3.7; SD = 1.5 months) reported there
also encloses the median OS of 2.4 months observed in
the control patients of this study.
At present, the exact pharmacological working prin-
ciple of VaL is unclear as VaL contains a wide variety
of biologically active constituents (lectins, viscotoxins,
other low-molecular-weight proteins, a chitin-binding
agglutinin, oligo- and polysaccharides, ﬂavonoids,
vesicles and triterpene acids) exerting cytotoxic,
apoptosis-inducing and immunostimulatory eﬀects.
For the subcutaneous injections used in this study, someimmunosignalling can be assumed, induced by perhaps
a variety of substances.
The study ﬁndings suggest VaL may be a non-toxic
and eﬀective second-line therapy that oﬀers a prolonga-
tion of OS as well as fewer disease-related symptoms for
patients with locally advanced or metastatic pancreatic
cancer. Further research on non-toxic and eﬀective can-
cer therapies is warranted.
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